OBJECTIVE: To describe the characteristics of multiple sclerosis (MS) presenting with severe cognitive impairment as its primary disabling manifestation. DESIGN: Retrospective case series. SETTING: Tertiary referral center. Patients Patients were identified through the Mayo Clinic data retrieval system (1996-2008) with definite MS (McDonald criteria) and severe cognitive impairment as their primary neurological symptom without accompanying significant MS-related impairment or alternative diagnosis for cognitive dysfunction. Twenty-three patients meeting inclusion criteria were compared regarding demographics, clinical course, and radiological features. MAIN OUTCOME MEASURES: Demographic, clinical, and radiological characteristics of the disease. RESULTS: Twelve patients were men. The median age of the first clinical symptom suggestive of central nervous system demyelination was 33 years, and severe MS-related cognitive impairment developed at a median age of 39 years. Cognitive impairment could be dichotomized as subacute fulminant (n = 9) or chronic progressive (n = 14) in presentation, which corresponded to subsequent relapsing or progressive MS courses. Study patients commonly exhibited psychiatric (65%), mild cerebellar (57%), and cortical symptoms and signs (eg, seizure, aphasia, apraxia) (39%). Fourteen of 21 (67%), where documented, smoked cigarettes. Brain magnetic resonance imaging demonstrated diffuse cerebral atrophy in 16 and gadolinium-enhancing lesions in 11. Asymptomatic spinal cord magnetic resonance imaging lesions were present in 12 of 16 patients (75%). Immunomodulatory therapies were generally ineffective in improving these patients. CONCLUSIONS: We describe patients with MS whose clinical phenotype is characterized by severe cognitive dysfunction and prominent cortical and psychiatric signs presenting as a subacute fulminant or chronic progressive clinical course. Cigarette smokers may be overrepresented in this phenotype.
OBJECTIVE: To describe the characteristics of multiple sclerosis (MS) presenting with severe cognitive impairment as its primary disabling manifestation. DESIGN: Retrospective case series. SETTING: Tertiary referral center. PatientsPatients were identified through the Mayo Clinic data retrieval system (1996-2008) with definite MS (McDonald criteria) and severe cognitive impairment as their primary neurological symptom without accompanying significant MS-related impairment or alternative diagnosis for cognitive dysfunction. Twenty-three patients meeting inclusion criteria were compared regarding demographics, clinical course, and radiological features. MAIN OUTCOME MEASURES: Demographic, clinical, and radiological characteristics of the disease. RESULTS: Twelve patients were men. The median age of the first clinical symptom suggestive of central nervous system demyelination was 33 years, and severe MS-related cognitive impairment developed at a median age of 39 years. Cognitive impairment could be dichotomized as subacute fulminant (n = 9) or chronic progressive (n = 14) in presentation, which corresponded to subsequent relapsing or progressive MS courses. Study patients commonly exhibited psychiatric (65%), mild cerebellar (57%), and cortical symptoms and signs (eg, seizure, aphasia, apraxia) (39%). Fourteen of 21 (67%), where documented, smoked cigarettes. Brain magnetic resonance imaging demonstrated diffuse cerebral atrophy in 16 and gadolinium-enhancing lesions in 11. Asymptomatic spinal cord magnetic resonance imaging lesions were present in 12 of 16 patients (75%). Immunomodulatory therapies were generally ineffective in improving these patients. CONCLUSIONS: We describe patients with MS whose clinical phenotype is characterized by severe cognitive dysfunction and prominent cortical and psychiatric signs presenting as a subacute fulminant or chronic progressive clinical course. Cigarette smokers may be overrepresented in this phenotype.
Authors: B Mark Keegan; Timothy J Kaufmann; Brian G Weinshenker; Orhun H Kantarci; William F Schmalstieg; M Mateo Paz Soldan; Eoin P Flanagan Journal: Neurology Date: 2016-09-16 Impact factor: 9.910
Authors: Reem F Bunyan; Bogdan F Gh Popescu; Jonathan L Carter; Richard J Caselli; Joseph E Parisi; Claudia F Lucchinetti Journal: Arch Neurol Date: 2011-04
Authors: Flavia Nelson; Sushmita Datta; Nereyda Garcia; Nigel L Rozario; Francisco Perez; Gary Cutter; Ponnada A Narayana; Jerry S Wolinsky Journal: Mult Scler Date: 2011-05-04 Impact factor: 6.312
Authors: Diana P Londoño; Kogulavadanan Arumaithurai; Eleni Constantopoulos; Michael R Basso; R Ross Reichard; Eoin P Flanagan; B Mark Keegan Journal: Brain Commun Date: 2022-06-22
Authors: W O Tobin; B F Popescu; V Lowe; I Pirko; J E Parisi; K Kantarci; J A Fields; M B Bruns; B F Boeve; C F Lucchinetti Journal: Mult Scler Date: 2015-10-07 Impact factor: 6.312